Abstract: Provided herein are novel AAV capsids and recombinant AAV vectors comprising the same. In certain embodiment, vectors comprising a novel AAV capsid show improved transduction of cardiac tissue and/or reduced targeting of liver tissue compared to a prior art AAV capsid.

Abstract: Provided herein are compositions including targeting peptides linked thereto or inserted in a targeting protein of a recombinant vector having at least one exogenous peptide comprising an amino acid sequence of N-x-(T/I/V/A)-(K/R) (SEQ ID NO: 47). Compositions providing such conjugates, targeting peptides, or recombinant vectors having a mutant capsid or envelope protein are provided as are uses thereof.

Abstract: A mutant soluble human Ace2 (hAce2) protein useful in preventing infection with betacoronaviruses, including SARS-CoV2 is provided, as are compositions useful in treating disease associated with betacoronavirus, including, e.g, COVID-19. Also provided are compositions containing same formulated for intranasal and/or intrapulmonary delivery, methods of making same and assays. The use of the rAAV compositions for preventing symptoms of COVID-19 infection in humans is provided.

Abstract: A recombinant adeno-associated virus (rAAV) vector comprising an AAV capsid having a heterogeneous population of vp1 proteins, a heterogeneous population of vp2 protein and a heterogeneous population of vp3 proteins. The capsid contains modified amino acids as compared to the encoded VP1 amino acid sequence, the capsid containing highly deamidated asparagine residues at asparagine-glycine pair, and further comprising multiple other, less deamidated asparagine and optionally glutamine residues.

Abstract: A recombinant adeno-associated virus (rAAV) vector comprising an AAV capsid having a heterogeneous population of vp1 proteins, a heterogeneous population of vp2 protein and a heterogeneous population of vp3 proteins. The capsid contains modified amino acids as compared to the encoded VP1 amino acid sequence, the capsid containing highly deamidated asparagine residues at asparagine-glycine pair, and further comprising multiple other, less deamidated asparagine and optionally glutamine residues. Methods of reducing deamidation in the AAV capsid of a rAAV are provided.